PHARMACEUTICAL INCOMPATIBILITES: A REVIEW
Incompatibility is defined as a change resulting and an undesirable product is formed, which may affect the safety, efficacy, appearance and stability of the pharmaceutical product. It is of three types. It includes physical, chemical and therapeutic incompatibilities. The below described article gives the detailed information about the types, causes and how to overcome these types of incompatibilities. The occurrence of chemical incompatibilities can be overcome by two methods which include method A&B.
2. Allen LV, Levison RS, Phisutsinthop D. Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets. Am J Hosp Pharm. 1977; 34:939-43
3. Roche VF. Improving pharmacy students’ understanding and long-term retention of acid–base chemistry. Am J Pharm Educ. 2007; 71: Article 122.
4. Arny HV, Fischelis RP. Principles of pharmacy. 4th ed. Philadelphia, PA: W. B. Saunders; 1937:25.
5. Skau K. Pharmacy is a science-based profession. Am J Pharm Educ. 2006; 71: Article 11. 6. Newton DW. Science-based pharmacy
6. North GT, Anderson WD. Interpreting, rather than reciting, the literature on drug compatibilities. Am J Hosp Pharm. 1995; 52:1400,1404.
7. Miller KW. Coordinating and optimizing educational efforts between basic science and clinical faculty: pharmaceutics. Am J Pharm Educ. 1975; 39:576-8.
8. Burkiewicz JS. Incompatibility of ceftriaxone sodium with lactated Ringer’s injection. Am J Health-Syst Pharm. 1999; 56:384. Letter.
9. Murray L. Physicians’ desk reference. 61st ed. Montvale, NJ: Thomson PDR; 2007:1026,1030.
10. Mendenhall A, Hoyt DB. Incompatibility of ketorolac tromethamine with haloperidol lactate and thiethylperazine maleate. Am J Hosp Pharm. 1994; 51:2964.
11. Newton DW. Physicochemical determinants of incompatibility and instability in injectable drug solutions and admixtures. IsJ Hosp Pharm. 1978; 35:1213-22.
12. Newton DW. Introduction: physicochemical determinants of incompatibility and instability of drugs for injection and infusion. In: Trissel LA. Handbook on inject able drugs. 3rd ed. Bethesda, MD: American Society of Hospital Pharmacists; 1983
13. Newton DW, Narducci WA. Extemporaneous formulations. In: King RE, ed. dispensing of medication. 9th ed. Easton, PA: Mack; 1984:281-5
14. Turco SJ. Intravenous admixtures. In: Troy DB, ed. Remington: the science and practice of pharmacy. 21st ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:847.
15. O’Donnell PB, Bokser AD. Stability of pharmaceutical products. In: Troy DB, ed. Remington: the science and practice of pharmacy. 21st ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:102536.
16. Driscoll DF, Joy J, Silvestre AP et al. Calcium (Ca) and phosphate (P) compatibility in low osmolality parenteral nutrition (PN) mixtures. ClinNutr. 2005; 24:695.
17. Trissel LA. Handbook on inject able drugs. 14th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2007
18. Lyman RA, Urdang G. In: Lyman RA, ed. Pharmaceutical compounding and dispensing. Philadelphia, PA: J. B. Lippincott; 1949:v.
19. Henderson LJ. A diagrammatic representation of equilibria between acids and bases in solution. J Am Chem. Soc. 1908; 30:954-60.
20. Hasselbalch KA. The calculation of the hydrogen number of the blood from the free and bound carbon dioxide of the same and the binding of oxygen by the blood as a function of the hydrogen number. Biochem Z. 1916; 78:112-44.
21. Lemke TL, Williams DA, Roche VF et al. Foye’s principles of medicinal chemistry. 6th ed. Baltimore, MD: Lippincott Williams& Wilkins; 2008:28-38,85,175. Primer Drug incompatibility357Am J Health-Syst Pharm—Vol66 Feb 15, 2009
22. Martin AN. Physical pharmacy. 4th ed. Philadelphia, PA: Lea &Febiger; 1993:223,130-2,144-6,149,169-70,179,214-5,2325,396-7.
23. Newton DW, Kluza RB. Prediction of phenytoin solubility in intravenous admixtures: physicochemical theory. Is J Hosp Pharm. 1980; 37:1647-51.
24. Newton DW, Kluza RB. PKa values of medicinal compounds in pharmacy practice. Drug IntelClin Pharm. 1978; 12:546-54.
25. Allen LV Jr, Popovich NG, Ansel HC. Ansel’s pharmaceutical dosage forms and delivery systems. 8th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2005:112, 145-6,152,338-41. 27.
26. 28. Lemke TL. Review of organic functional groups. 4th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2003:4,46-7,123, 132-40.
27. Gennaro AR. Organic pharmaceutical chemistry. In: Troy DB, ed. Remington: the science and practice of pharmacy. 21st ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:391-400.
28. Lien EJ. Molecular structure, properties, and states of matter. In: Troy DB, ed. Remington: the science and practice of pharmacy. 21st ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005: 172-3.
29. Gupta PK. Solutions and phase equilibria. In: Troy DB, ed. Remington: the science and practice of pharmacy. 21st ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:214-5,220-4.
30. Berge SM, Bighley LD, Monk house DL. Pharmaceutical salts. J Pharm Sci. 1977; 66:1-19. 33.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).